Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Generate Biomedicines r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $82.25M | +37.7% |
| Q2 FY2026 | Jun 30, 2026 | $64.33M | +37.4% |
| Q1 FY2026 | Mar 31, 2026 | $57.81M | – |
| Q3 FY2025 | Sep 30, 2025 | $62.15M | – |
| Q2 FY2025 | Jun 30, 2025 | $59.74M | – |
| Q1 FY2025 | Mar 31, 2025 | $46.83M | – |
See a number that looks wrong?